Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Baxter
Harvard Business School
Chubb
Accenture

Generated: August 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,533,053

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,533,053
Title:High concentration olopatadine ophthalmic composition
Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.
Inventor(s): Gamache; Daniel A. (Arlington, TX), Alani; Laman (Fort Worth, TX), Ghosh; Malay (Fort Worth, TX), Galan; Francisco Javier (Teia, ES), Perdiguer; Nuria Carreras (Barcelona, ES), Singh; Onkar N. (Arlington, TX)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:14/304,124
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,533,053
Patent Claims: 1. An aqueous ophthalmic solution for treatment of ocular allergic conjunctivitis, the solution comprising: at least 0.67 w/v % olopatadine dissolved in the solution; PEG having a molecular weight of 200 to 800; polyvinylpyrrolidone; a cyclodextrin selected from the group consisting of SAE-.beta.-cyclodextrin, hydroxypropyl-.beta.-cyclodextrin and hydroxypropyl-.gamma.-cyclodextrin; and water.

2. A solution as in claim 1 further comprising benzalkonium chloride.

3. A solution as in claim 2 further comprising borate.

4. A solution as in claim 3 further comprising a polyol.

5. A solution as in claim 1 wherein the concentration of olopatadine is no greater than 1.0 w/v %.

6. A solution as in claim 1 wherein the concentration of PEG is 2.0 w/v % to 6.0 w/v %, the concentration of polyvinylpyrrolidone is 2.0 w/v % to 6.0 w/v % and the concentration of cyclodextrin is at least 0.5 w/v % but no greater than 2.0 w/v %.

7. A solution as in claim 1 wherein the solution provides more than a 1.0 unit difference relative to vehicle in relief of redness at onset of action according to FDA accepted CAC model.

8. An aqueous ophthalmic solution for treatment of ocular allergic conjunctivitis, the solution comprising: at least 0.67 w/v % olopatadine dissolved in the solution; PEG having a molecular weight of 200 to 800; polyvinylpyrrolidone; a cyclodextrin selected from the group consisting of hydroxybrobyl-.beta.-cyclodextrin and hydroxypropyl-.gamma.-cyclodextrin; benzalkonium chloride; hydroxypropylmethyl cellulose; and water.

9. A solution as in claim 8 further comprising borate.

10. A solution as in claim 9 further comprising a polyol.

11. A solution as in claim 8 wherein the concentration of olopatadine is no greater than 1.0 w/v %.

12. A solution as in claim 8 wherein the concentration of PEG is 2.0 w/v % to 6.0 w/v %, the concentration of polyvinylpyrrolidone is 2.0 w/v % to 6.0 w/v % and the concentration of cyclodextrin is at least 0.5 w/v % but no greater than 2.0 w/v %.

13. A solution as in claim 8 wherein the solution provides more than a 1.0 unit difference relative to vehicle in relief of redness at onset of action according to FDA accepted CAC model.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
AstraZeneca
Citi
Mallinckrodt
Covington
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.